Eldecalcitol - CAS 104121-92-8
Catalog number:
B0084-305756
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C30H50O5
Molecular Weight:
490.72
COA:
Inquire
Targets:
VD/VDR
Description:
Eldecalcitol, a vitamin D analog, has strong effects to reduce calcium reabsorption into the body from bones, therefore increasing bone mineral density, and to increase calcium absorption in intestines.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-305756 1 mg $998 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
MSDS:
Inquire
1.Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials.
Xu Z1, Fan C2, Zhao X3, Tao H1. Drug Des Devel Ther. 2016 Jan 28;10:509-17. doi: 10.2147/DDDT.S84264. eCollection 2016.
OBJECTIVE: Eldecalcitol (ELD) is an active form of vitamin D analog that has been approved for the treatment of osteoporosis in Japan. Over recent years, a number of multicenter, randomized controlled clinical trials have been conducted. Our goal is to comprehensively summarize the results from these studies.
2.Eldecalcitol, in Combination with Bisphosphonate, Is Effective for Treatment of Japanese Osteoporotic Patients.
Mukaiyama K1, Uchiyama S, Nakamura Y, Ikegami S, Taguchi A, Kamimura M, Kato H. Tohoku J Exp Med. 2015;237(4):339-43. doi: 10.1620/tjem.237.339.
Alfacalcidol (ALF) and eldecalcitol (ELD) are vitamin D analogues that can be combined with anti-resorption drugs, such as bisphosphonate (BP) for the treatment of osteoporosis (OP). There has been no report comparing the effects of those vitamin D analogs in combination with BPs. Twenty female patients with OP were enrolled, and all of them were treated with ALF and BPs. After switching from ALF to ELD, we examined the effectiveness of ALF and ELD. The averaged age was 69.4 years and the period of BP usage was between 1 to 13.4 years (mean period was 3.7 years). Serum corrected calcium, serum inorganic phosphorus, serum bone specific alkaline phosphatase (BAP), and serum tartrate-resistant acid phosphatase (TRACP)-5b were measured prior to ELD and at 6 months afterwards. Bone mineral density (BMD) of the lumbar spine (L-BMD), femoral neck, and total hip BMD were assessed one year before, prior to, and one year after ELD therapy commencement.
3.Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
Iba K1, Sonoda T2, Takada J3, Dohke T4, Yamashita T4. J Bone Miner Metab. 2016 Jan 30. [Epub ahead of print]
We investigated whether eldecalcitol has further significant effects on bone metabolic markers and bone mineral density (BMD) in osteoporosis patients having undergone long-term bisphosphonate treatment. Eldecalcitol treatment was initiated in 48 postmenopausal osteoporosis patients who had undergone bisphosphonate treatment with or without alfacalcidol treatment for more than 2 years (average period 6.3 years). Age, height, weight, total muscle volume, total fat volume, estimated glomerular filtration rate, and BMD at the lumbar spine, total hip, and distal third of the radius were measured as background data for each patient. Serum alkaline phosphatase, tartrate-resistant acid phosphatase 5b, calcium, and phosphate levels were measured at the baseline and 3 and 12 months after the initiation of eldecalcitol treatment, and BMD was measured at the baseline and 12 months after the initiation of eldecalcitol treatment. Tartrate-resistant acid phosphatase 5b level was significantly decreased at 3 and 12 months after the initiation of eldecalcitol treatment in comparison with the baseline level.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related VD/VDR Products


CAS 57333-96-7 Tacalcitol

Tacalcitol
(CAS: 57333-96-7)

Tacalcitol promotes normal bone development by regulating calcium and modulates immunological and inflammatory processes. lt induces nerve growth factor product...

CAS 93129-94-3 Tacalcitol monohydrate

Tacalcitol monohydrate
(CAS: 93129-94-3)

Tacalcitol monohydrate is a VDR-like Receptor promotes normal bone development by regulating calcium. It modulates immunological and inflammatory processes and ...

CAS 126860-83-1 MC 1046

MC 1046
(CAS: 126860-83-1)

MC 1046 is a vitamin D3 analogue with similar effects. Impurity of Calcipotriol, an antipsoriatic.

CAS 147657-22-5 Calcipotriol monohydrate

Calcipotriol monohydrate
(CAS: 147657-22-5)

Calcipotriol increased hCAP18 mRNA expression in IL-17/IL-22-stimulated keratinocytes. However, LL37 peptide in the culture supernatants was reduced by calcipot...

CAS 131875-08-6 Lexacalcitol

Lexacalcitol
(CAS: 131875-08-6)

KH1060 metabolism could be blocked by the cytochrome P450 inhibitor, ketoconazole. KH1060 was not an effective competitor of C24 oxidation of 1alpha,25-(OH)2D3....

CAS 41294-56-8 Alfacalcidol

Alfacalcidol
(CAS: 41294-56-8)

A synthetic analog of Calcitiol (the hormonal form of vitamin D3), which shows identical potency with respect to stimulation of intestinal calcium absorption an...

CAS 112827-99-3 24R-Calcipotriol

24R-Calcipotriol
(CAS: 112827-99-3)

24R-Calcipotriol is an impurity of Calcipotriol, which is a ligand of VDR-like receptors.

CAS 72203-93-1 Calcitetrol

Calcitetrol
(CAS: 72203-93-1)

Calcitetrol is the hormonally active form of vitamin D with three hydroxyl groups. It increases blood calcium levels ([Ca2+]) by promoting absorption of dietary...

CAS 50-14-6 Vitamin D2

Vitamin D2
(CAS: 50-14-6)

Vitamin D2 is a selective inhibitor of mammalian DNA polymerase A (pol A) with IC50 of 123 mM.

CAS 66791-71-7 Impurity B of Calcitriol

Impurity B of Calcitriol
(CAS: 66791-71-7)

Impurity B of Calcitriol is the hormonally active form of vitamin D, and Calcitriol is the active metabolite of vitamin D3 that activates the vitamin D receptor...

CAS 54573-75-0 Doxercalciferol

Doxercalciferol
(CAS: 54573-75-0)

Doxercalciferol (Hectorol; 1.alpha.-Hydroxyvitamin D2) is a synthetic analog of vitamin D; is a Vitamin D2 analog that acts as a vitamin D receptor activator (V...

CAS 55721-11-4 Secalciferol

Secalciferol
(CAS: 55721-11-4)

Secalciferol is a metabolite of Vitamin D, a possibly anti-inflammatory steroid which is involved in bone ossification. lt mediates calcium and phosphorus homeo...

CAS 104121-92-8 Eldecalcitol

Eldecalcitol
(CAS: 104121-92-8)

Eldecalcitol, a vitamin D analog, has strong effects to reduce calcium reabsorption into the body from bones, therefore increasing bone mineral density, and to ...

CAS 21343-40-8 Ercalcidiol

Ercalcidiol
(CAS: 21343-40-8)

A metabolite of Vitamin D2

CAS 86307-44-0 Impurity C of Calcitriol

Impurity C of Calcitriol
(CAS: 86307-44-0)

Impurity C of Calcitriol is the impurity C of Calcitriol, which is the active metabolite of vitamin D3 that activates the vitamin D receptor (VDR).

CAS 63283-36-3 Calcifediol monohydrate

Calcifediol monohydrate
(CAS: 63283-36-3)

Calcifediol monohydrate is a prehormone that is produced in the liver by hydroxylation of vitamin D3 (cholecalciferol) by the enzyme cholecalciferol 25-hydroxyl...

CAS 67-97-0 Cholecalciferol

Cholecalciferol
(CAS: 67-97-0)

Cholecalciferol is a naturally occuring form of vitamin D which is obtained from dietary sources, such as fish, or through the conversion of 7-dehydrocholestero...

LG190155
(CAS: 233268-78-5)

LG190155 is a moderately potent VDR agonist.

CAS 112828-09-8 (24R)-MC 976

(24R)-MC 976
(CAS: 112828-09-8)

(24R)-MC 976 is a Vitamin D3 derivative.

CAS 19356-17-3 Calcifediol

Calcifediol
(CAS: 19356-17-3)

Calcifediol is a major circulating metabolite of vitamin D3 and acts as a competitive inhibitor with an apparent Ki of 3.9 μM. It also suppresses PTH secretion ...

Chemical Structure

CAS 104121-92-8 Eldecalcitol

Quick Inquiry

Verification code

Featured Items